SCHEMBL722933

SCHEMBL722933

COc1cc(-c2cc3nccc(-c4cnn(C)c4)c3o2)ccc1OCCN

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.39
MCHR1 Q99705 1/20 0.39
BRD4 O60885 1/20 0.38
LOXL2 Q9Y4K0 2/20 0.38
FYN P06241 1/20 0.38
TTK P33981 10/20 0.37
CCNA2 P20248 2/20 0.37
CDK2 P24941 2/20 0.37
NTRK1 P04629 1/20 0.37
CSF1R P07333 1/20 0.37
NTRK3 Q16288 1/20 0.37
NTRK2 Q16620 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721802 0.84 FYN (0.51) FYNTTKCCNA2CDK2
SCHEMBL722228 0.82 PDE4C (0.43) METBRD4FYNTTKCCNA2
SCHEMBL722232 0.82 IRAK1 (0.40) METMCHR1TTKCSF1R
SCHEMBL725506 0.80 KCNH2 (0.43) METTTKCCNA2CDK2
SCHEMBL10268949 0.79 AURKB (0.46) METBRD4
SCHEMBL724888 0.79 ACVR2A (0.48)
SCHEMBL721816 0.79 LRRK2 (0.45) METTTKCCNA2CDK2
SCHEMBL725161 0.77 PDE4C (0.42) METBRD4FYNTTK
SCHEMBL724620 0.77 PDE4A (0.51)
SCHEMBL722397 0.77 AURKB (0.44) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB MET 1482/4885MCHR1 3921/4885BRD4 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.